These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization]. Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182 [TBL] [Abstract][Full Text] [Related]
8. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. Malone-Lee J; Shaffu B; Anand C; Powell C J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895 [TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of bunazosin hydrochloride for the treatment of voiding disturbances due to neurogenic bladder--a double-blind study]. Koyanagi T; Togashi M; Maru A; Orikasa S; Soma F; Shimazaki J; Yasuda K; Aso Y; Honma Y; Miyake K Hinyokika Kiyo; 1990 Oct; 36(10):1233-52. PubMed ID: 1979900 [TBL] [Abstract][Full Text] [Related]
10. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Goldenberg MM Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Kennelly MJ; Lemack GE; Foote JE; Trop CS Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264 [TBL] [Abstract][Full Text] [Related]
14. [Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly]. Uchibayashi T; Nakajima K; Nihino A; Hisazumi H Hinyokika Kiyo; 1991 Sep; 37(9):1077-85. PubMed ID: 1785418 [TBL] [Abstract][Full Text] [Related]
15. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ; Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176 [TBL] [Abstract][Full Text] [Related]
16. [Therapeutic effects of intrarectal administration of oxybutynin]. Radziszewski P; Borkowski A Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351 [TBL] [Abstract][Full Text] [Related]
17. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. Mizunaga M; Miyata M; Kaneko S; Yachiku S; Chiba K Paraplegia; 1994 Jan; 32(1):25-9. PubMed ID: 8015832 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731 [TBL] [Abstract][Full Text] [Related]
19. [Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women]. Serrano Brambila EA; Quiroga Avila RG; Lorenzo Monterrubio JL; Moreno Aranda J Ginecol Obstet Mex; 2000 Apr; 68():174-81. PubMed ID: 10824450 [TBL] [Abstract][Full Text] [Related]
20. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]